Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

This is a Study That Aims to Estimate the Effect of Maternal Body Mass Index on the Prophylactic Dose of Norepinephrine Infusion for Preventing Hypotension in Parturient After Spinal Anesthesia

11 juillet 2026 mis à jour par: Ain Shams University

Effect of Maternal Body Mass Index on the Prophylactic Dose of Norepinephrine Infusion for Preventing Hypotension in Parturient After Spinal Anesthesia

This is a randomized, double-blinded controlled study that aims to estimate the effect of maternal body mass index on the prophylactic dose of norepinephrine infusion for preventing hypotension in parturient after spinal anesthesia.

Aperçu de l'étude

Statut

Pas encore de recrutement

Description détaillée

This is a randomized, double-blinded controlled study that aims to estimate the effect of maternal body mass index on the prophylactic dose of norepinephrine infusion for preventing hypotension in parturient after spinal anesthesia.

Routine preoperative investigations will be done to all patients including laboratory investigations as (complete blood picture, prothrombin time and partial thromboplastin time), age and BMI will be recorded.

All the patients will be fasting for solid food for 6-8 hours and for clear fluids for 4 hours before surgery.

Upon entry into the operating theater, all patients will be placed under standard American Society of Anesthesiologist (ASA) monitoring including 5-lead electrocardiography, pulse oximetry and non-invasive blood pressure. Baseline values of systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) and mean blood pressure (MBP) will be measured in supine position with left uterine displacement (15 degree wedge under the right buttock) and recorded as the arithmetic mean of three consecutive measurements at least 2 min intervals with a difference of less than 10%.

As per standard practice, SBP, DBP, MBP, HR and pulse oximetry measurements will be recorded in every 2 min throughout the surgery. An 18-gauge cannula will be inserted into a large vein, The patients will receive no premedication. The study period will be the interval between the initiation of spinal injection and delivery of the fetus .

Subarachnoid block will be performed through L3-4 or L4-5 intervertebral space in the sitting position. A solution of 12.5 mg 0.5% hyperbaric bupivacaine plus 25 mic fentanyl will be injected into subarachnoid space using a 25-gauge pencil point spinal needle. After completion of subarachnoid injection, patients will be immediately placed supine on the operating table with left uterine displacement using a 15° wedge .

The highest level of sensory blockade will be assessed using a sterile needle, surgery will be permitted after a bilateral T6 sensory block .

To assure blinding, the study group will be known only to the research assistant, who would be responsible for each step of the NE administration including starting dose of NE infusion, applying a bolus dose or cessation of the infusion of NE according to the study protocol .

Immediately after the injection of the spinal anesthetic, patients will have a norepinephrine protocol corresponding to the randomized group. The study drug will be started intravenously at a rate of 50 ml/h, Lactated Ringer's solution warmed at 37°C will also administered, starting with a loading dose of 10 ml/kg given rapidly over 15 minutes and will then be adjusted to a slow maintenance flow rate to keep the vein open .

After delivery, an intravenous infusion of oxytocin (20 IU) will be slowly administered. After the end of surgery, the mother will be transported to the recovery room with routine monitoring .

NE infusion will be stopped 5 min after delivery in all patients . The intraoperative period will be divided into 2 consecutive periods . The first period is called the post-spinal period and will include the period between the completion of subarachnoid block and the time of delivery.

The subsequent period between the time of delivery and the end of the surgery will be called the post-delivery period.

All complications will be entitled according to the period in which they occurred. Accordingly, post spinal hypotension (PSH) and post delivery hypotension (PDH) will be defined as a reduction in SBP of 20% or more of the baseline value before and after the delivery, respectively .

Similarly, post-spinal severe hypotension (PSSH) and post-delivery severe hypotension (PDSH) will be defined as a decrease in SBP of 40% or more from the baseline value before and after the delivery respectively.

Management of complications: .

  1. If PSH or PDH was developed, a bolus of 10 mg ephedrine will be administered.
  2. If hypotension persisted after 2 min, a repeated dose of 10 mg ephedrine i.v. will be administered again.
  3. If PSSH or PDSH occurred, 15 mg ephedrine i.v. bolus will administered.
  4. In case of bradycardia (heart rate less than 60 beats per min ) without maternal hypotension, NE infusion will be stopped.
  5. If bradycardia persists for 2 min despite discontinuation of NE infusion, 0.5 mg of atropine i.v. bolus will be administered.
  6. Moreover, if the heart rate falls below 50 beats per min , 0.5 mg atropine i.v. bolus will be administered without waiting for 2 min. As soon as the HR increases above 60 beats per min, NE infusion will be started again at the same infusion dose corresponding to the NE group that the patient is randomized.
  7. If bradycardia is accompanied by hypotension, 10 mg ephedrine i.v. bolus will be administered.
  8. In contrast to hypotension, if the SBP is found to be 20% above the basal value, the NE infusion will be stopped and recorded as a hypertensive episode. If the systolic blood pressure falls below this determined hypertensive value, NE will be restarted at the same dose.
  9. Incidence of maternal complication as nausea and vomiting will be recorded and treated with granitryl (1 mg IV) Apgar score after delivery. Apgar score at 1 and 5 min will be recorded after delivery by the attending pediatric physician.

Hemodynamic changes mentioned above and the number of interventions including administration of ephedrine or atropine, stopping or re-starting of NE infusion, which will be applied by the physician to overcome the hemodynamic consequences of spinal anesthesia will all be recorded until the patient leaves the operating room.

Type d'étude

Interventionnel

Inscription (Estimé)

80

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Abbasia
      • Cairo, Abbasia, Egypte, 00202
        • Ain Shams

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • A normal singleton pregnancy with a gestational age of ≥ 37 weeks. 18-40 years old pregnant women scheduled for elective C/S under spinal anesthesia.

Exclusion Criteria:

  • Any absolute contraindication to spinal block, Neurological or cardiac disorder, Basal systolic blood pressure above 140 mmHg or below 100 mmHg, Peripartum bleeding or emergent situations both for fetus and mother, Those who refused to participate in the study were excluded Known fetal abnormality, intrauterine growth restriction, Obstetric complication (ruptured membranes, placenta previa, placental abruption),

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Non_obese + NE 0 mic/kg/min
Non_obese Patients BMI <30 kg/m2 receiving placebo (normal saline )infusion after spinal anesthesia.
normal saline infusion post spinal anesthesia .
Comparateur actif: Non_obese + NE 0.025mic/kg/min
Non_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.025mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Comparateur actif: Non_obese + NE 0.05mic/kg/min
Non_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.05mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Comparateur actif: Non_obese + NE 0.075mic/kg/min
Non_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.075mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Comparateur actif: Non_obese + NE 0.1mic/kg/min
Non_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.1mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Comparateur placebo: Obese + NE 0 mic/kg/min
Obese Patients BMI >30 kg/m2 receiving placebo (normal saline )infusion after spinal anesthesia.
normal saline infusion post spinal anesthesia .
Comparateur actif: Obese + NE 0.025 mic/kg/min
Obese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.025 mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Comparateur actif: Obese + NE 0.05 mic/kg/min
Obese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.05 mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Comparateur actif: Obese + NE 0.075 mic/kg/min
Obese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.075 mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Comparateur actif: Obese + NE 0.1 mic/kg/min
Obese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.1 mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of hypotension after spinal anesthesia
Délai: From spinal anesthesia until delivery of the fetus.
Hypotension defined as a ≥20% decrease in systolic blood pressure from baseline.
From spinal anesthesia until delivery of the fetus.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Reactive hypertension
Délai: From spinal anesthesia until the end of surgery.
Incidence of systolic blood pressure ≥20% above baseline.
From spinal anesthesia until the end of surgery.
Bradycardia
Délai: From spinal anesthesia until the end of surgery.
Heart rate <60 beats/min.
From spinal anesthesia until the end of surgery.
Nausea and vomiting
Délai: From spinal anesthesia until the end of surgery.
Incidence of maternal nausea and/or vomiting.
From spinal anesthesia until the end of surgery.
Apgar score at 1 minute
Délai: 1 minute after delivery.
Neonatal Apgar score.
1 minute after delivery.
Apgar score at 5 minutes
Délai: 5 minutes after delivery.
Neonatal Apgar score.
5 minutes after delivery.
Number of rescue interventions
Délai: From spinal anesthesia until the patient leaves the operating room.
Number of ephedrine doses, atropine doses, and norepinephrine infusion interruptions/restarts.
From spinal anesthesia until the patient leaves the operating room.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

9 juillet 2026

Achèvement primaire (Estimé)

20 janvier 2027

Achèvement de l'étude (Estimé)

20 avril 2027

Dates d'inscription aux études

Première soumission

11 juillet 2026

Première soumission répondant aux critères de contrôle qualité

11 juillet 2026

Première publication (Réel)

15 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

15 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 juillet 2026

Dernière vérification

1 juillet 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • FMASU MD 46/2026

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner